Wall Street nicked shares of Vertex Pharmaceuticals Inc. on word of results from two Phase IIb trials with its protease inhibitor telaprevir, as investors apparently were turned off by somewhat lower than expected sustained viral response (SVR), though the drug beat standard of care. (BioWorld Today)